



PATIENT GROUP DIRECTION EEAST 2022-25

Administration of Tranexamic Acid Injection

Clinical Condition	
Indications	Patient with significant internal or external haemorrhage suspected
Inclusion criteria	<ul style="list-style-type: none"> • Injured patients with traumatic injury where serious bleeding (significant internal/external haemorrhage) is suspected, within 3 hours of injury • Patients aged over 18 years old with head injury and a GCS of 12 or less, within 3 hours of injury • Post-Partum Haemorrhage within 3 hours of delivery or onset and bleeding is estimated to be >500mls and continuing • Haemorrhage due to disorders of obstetric origin e.g, antepartum haemorrhage, suspected placental abruption
Exclusion criteria	<p>Critical intervention required i.e., if critical interventions leave insufficient time for administration of tranexamic acid.</p> <p>Bleeding now stopped</p> <p>Known allergy to tranexamic acid</p> <p>Haemorrhage suspected of occurring more than three hours prior to treatment</p>
Cautions/Need for further advice	<p>Rapid intravenous injection might rarely cause hypotension.</p> <p>There is good data that this treatment is safe and effective (giving a 9% reduction in the number of deaths in patients in the CRASH2 trial).</p> <p>Manufacturer’s list of clinical precautions:</p> <p>https://www.medicines.org.uk/emc/product/1220/smpc#CLINICAL PRECAUTIONS</p>
Pregnancy and breast feeding	<p>No evidence of harm in pregnancy. However, manufacturer advises use only if potential benefit outweighs risk—crosses the placenta.</p> <p>Manufacturer’s information:</p> <p>https://www.medicines.org.uk/emc/product/1220/smpc#PREGNANCY</p>
Action to be taken if patient is excluded	<p>Ensure the medical details and all advice given and the actions of the patient (including guardian or relative) are handed over to the receiving facility.</p> <p>Seek advice from a medical practitioner</p>
Action to be taken if patient declines treatment	<p>Ensure medical records detail the advice given and the actions of the patient (including guardian or relative)</p> <p>Seek advice from a medical practitioner if present</p>

PATIENT GROUP DIRECTION EEAST 2021-23

Administration of Tranexamic Acid Injection

Drug Details							
Name, form & strength of	Tranexamic Acid 500mg in 5ml ampoule (100 mg/ml).						
Legal Status	Prescription Only Medicine [POM]						
Licensed or Unlicensed	Licensed						
Route/Method	Intravenous or Intraosseous (off-licence use) <u>Must not be administered IM</u>						
Dosage	Adults and children ≥12 years						
	Age	Initial Dose	Repeat Dose	Dose Interval	Concentration	Volume	Max Dose
	≥12 years-Adult	1gram	NONE	N/A	100mg/ml	10mls	1g
	Administer SLOWLY as an IV/IO BOLUS over 1-2 minutes. Give a large flush after administration and monitor blood pressure carefully for possible hypotensive response giving appropriate fluid challenges where necessary to maintain perfusion pressure.						
	<12 Years 15mg/kg or use dosing table below						
	If required to aid slow IV administration draw up dose in a syringe with Sodium Chloride 0.9% to a total of 10ml. (e.g., 6-year-old, draw up 3ml of TXA, add 7ml of NaCl to make 10ml total volume)						
	Age	Initial Dose	Repeat Dose	Dose Interval	Concentration	Dose Volume	Max Dose
	11 years	500mg	NONE	N/A	100mg/ml	5ml	500 mg
	10 years	500mg	NONE	N/A	100mg/ml	5ml	500 mg
	9 years	450mg	NONE	N/A	100mg/ml	4.5mls	450 mg
	8 years	400mg	NONE	N/A	100mg/ml	4ml	400 mg
	7 years	350mg	NONE	N/A	100mg/ml	3.5ml	350 mg
	6 years	300mg	NONE	N/A	100mg/ml	3ml	300 mg
	5 years	300mg	NONE	N/A	100mg/ml	3ml	300 mg
	4 years	250mg	NONE	N/A	100mg/ml	2.5ml	250 mg
	3 years	200mg	NONE	N/A	100mg/ml	2ml	200 mg
	2 years	200mg	NONE	N/A	100mg/ml	2ml	200 mg
	18 months	150mg	NONE	N/A	100mg/ml	1.5ml	150 mg
	12 months	150mg	NONE	N/A	100mg/ml	1.5ml	150 mg
	9 months	150mg	NONE	N/A	100mg/ml	1.5ml	150 mg
	6 months	100mg	NONE	N/A	100mg/ml	1ml	100 mg
	3 months	100mg	NONE	N/A	100mg/ml	1ml	100 mg
	1 month	50mg	NONE	N/A	100mg/ml	0.5ml	50 mg
	Birth	50mg	NONE	N/A	100mg/ml	0.5ml	50 mg

PATIENT GROUP DIRECTION EEAST 2021-23

Administration of Tranexamic Acid Injection

Drug Details	
Frequency	Single dose
Duration of treatment	Single dose
Maximum or minimum treatment period	Single episode
Quantity to administer	As above
Adverse effects	<p>Rapid injection might rarely cause hypotension. Nausea, vomiting and diarrhoea</p> <p>Possible visual disturbances including visual impairment, vision blurred, impaired colour vision</p> <p>Manufacturer's listing: https://www.medicines.org.uk/emc/product/1220/smpc#UNDESIRABLE_EFFECTS</p> <p>If any untoward reactions occur these must be reported using the Yellow Card system to the MHRA http://yellowcard.mhra.gov.uk/</p> <p>If such a report is made an internal Trust Incident Report form must be completed</p>
Advice to patient/carer	The effects and side effects of the procedure must be explained to the patient and consent gained before administration.
Follow up	All patients who have received Tranexamic Acid must be transported to hospital and handed over to the care of a suitably qualified doctor or nurse.
Key References	<p>BNF: JRCALC: https://bnf.nice.org.uk/drug/tranexamic-acid.html</p> <p>BNFc: https://bnfc.nice.org.uk/drug/tranexamic-acid.html</p> <p>eMC (Accord Healthcare): https://www.medicines.org.uk/emc/product/8953/smpc</p> <p>JRCALC: https://jrcahc-web.netlify.app/#/tab/dash/drug/D0360</p>



Authorisation by EEAST	
Medical Advisor	Name: Dr Tom Davis Position: Medical Director GMC: 6077328 Signature:  Date: 9 th June 2021
Trust Pharmacist	Name: Dr Brian Wells Position: Pharmacist (Wells Offshore) GPhC: 2016621 Signature:  Date: 19 th May 2021